Table II.
Effects of NAC on tAOC and 8-iso-PGF2α in serum and myocardium among the groups.
| Control group (n=10) | HF group (n=12) | NAC group (n=13) | P-value | |
|---|---|---|---|---|
| tAOC | ||||
| Serum (U/ml) | 15.09±4.03 | 8.86±2.21a | 13.23±2.92b | <0.001 |
| Myocardium (U/mg) | 1.65±0.20 | 1.26±0.30a | 1.58±0.19b | 0.001 |
| 8-iso-PGF2α | ||||
| Serum (pg/mg) | 53.22±5.33 | 199.58±19.16a | 85.01±15.12a,b | <0.001 |
| Myocardium (pg/mg) | 78.08±4.41 | 235.49±18.52a | 99.48±12.16a,b | <0.001 |
| GSH (unit/ml) | 28.18±2.58 | 12.95±2.87a | 22.39±2.75a,b | <0.001 |
P-values are based on analysis of variance test. Pair-wise multiple comparisons between groups were determined using Bonferroni’s test with α=0.017 adjustment.
a
P<0.05 between the indicated group and the control group;
b
P<0.05 between the indicated group and the HF group.
NAC, N-acetylcysteine; HF group, untreated heart failure group; tAOC, total anti-oxidative capacity; 8-iso-PGF2α 8-iso-prostaglandin F2α; GSH, glutathione.